CN108602827B - Bruton酪氨酸激酶的咪唑并吡嗪抑制剂 - Google Patents

Bruton酪氨酸激酶的咪唑并吡嗪抑制剂 Download PDF

Info

Publication number
CN108602827B
CN108602827B CN201680077913.0A CN201680077913A CN108602827B CN 108602827 B CN108602827 B CN 108602827B CN 201680077913 A CN201680077913 A CN 201680077913A CN 108602827 B CN108602827 B CN 108602827B
Authority
CN
China
Prior art keywords
cancer
amino
benzamide
imidazo
pyrazin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201680077913.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN108602827A (zh
Inventor
T.巴夫
E.德兹瓦特
S.费尔凯克
N.胡根布姆
D.德蒙
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Acerta Pharma BV
Original Assignee
Acerta Pharma BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acerta Pharma BV filed Critical Acerta Pharma BV
Publication of CN108602827A publication Critical patent/CN108602827A/zh
Application granted granted Critical
Publication of CN108602827B publication Critical patent/CN108602827B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CN201680077913.0A 2015-11-06 2016-11-04 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂 Active CN108602827B (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562252420P 2015-11-06 2015-11-06
US62/252420 2015-11-06
US201562261228P 2015-11-30 2015-11-30
US62/261228 2015-11-30
PCT/IB2016/056661 WO2017077507A1 (en) 2015-11-06 2016-11-04 Imidazopyrazine inhibitors of bruton's tyrosine kinase

Publications (2)

Publication Number Publication Date
CN108602827A CN108602827A (zh) 2018-09-28
CN108602827B true CN108602827B (zh) 2021-08-20

Family

ID=57286764

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680077913.0A Active CN108602827B (zh) 2015-11-06 2016-11-04 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂

Country Status (6)

Country Link
US (2) US10736893B2 (https=)
EP (2) EP3865485A1 (https=)
JP (1) JP6890602B2 (https=)
CN (1) CN108602827B (https=)
MA (1) MA43162A (https=)
WO (1) WO2017077507A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN108602827B (zh) * 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
JP6715357B2 (ja) * 2016-06-30 2020-07-01 杭州三因泰医薬科技有限公司Ｈａｎｇｚｈｏｕ Ｓａｎｙｉｎｔａｉ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏ．， Ｌｔｄ． イミダゾピリジンアミンフェニル誘導体およびその使用
CN108101905A (zh) * 2016-11-24 2018-06-01 中国科学院上海药物研究所 嘧啶并[5,4-b]吲嗪或嘧啶并[5,4-b]吡呤化合物、其制备方法及用途
KR102627756B1 (ko) * 2017-03-22 2024-01-23 쑤저우 바이지부공 파마수티컬 테크널러지 컴퍼니 리미티드 브루톤 타이로신 키나제 억제제
US10800787B2 (en) 2017-04-20 2020-10-13 Apotex Inc. Process for the preparation of acalabrutinib
WO2019013562A1 (ko) * 2017-07-12 2019-01-17 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
KR102384924B1 (ko) 2017-07-12 2022-04-08 주식회사 대웅제약 신규한 1h-피라졸로피리딘 유도체 및 이를 포함하는 약학 조성물
CN109836416B (zh) * 2017-11-27 2023-02-03 苏州鹏旭医药科技有限公司 一种化合物的制备方法
WO2019090269A1 (en) * 2017-11-06 2019-05-09 Peng Wang Processes to produce acalabrutinib
CN108129483B (zh) * 2018-01-26 2019-06-04 成都施贝康生物医药科技有限公司 一种btk抑制剂及其应用
CN108250186B (zh) * 2018-02-07 2020-01-14 杭州科巢生物科技有限公司 Acalabrutinib及其中间体的合成方法
KR102106821B1 (ko) 2018-04-27 2020-05-06 재단법인대구경북과학기술원 이브루티닙을 유효성분으로 포함하는 퇴행성 뇌질환의 예방 또는 치료용 약학적 조성물
CN109053780B (zh) * 2018-07-05 2020-09-29 浙江合聚生物医药有限公司 一种抗肿瘤药物Acalabrutinib关键中间体的制备方法
US12024520B2 (en) * 2018-08-29 2024-07-02 Acerta Pharma B.V. Processes for the preparation of 4-{8-amino-3-[(2S)-1-(but-2-ynoyl)-pyrrolidin-2-yl]imidazo[1,5-a]-pyrazin-1-yl}N-(pyridin-2-yl)-benzamide
US11891405B2 (en) 2018-09-14 2024-02-06 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Furo[3,4-b]pyrrole-containing BTK inhibitor
US12285182B2 (en) 2018-10-10 2025-04-29 Innova Vascular, Inc. Devices and methods for removing an embolus
US20220143049A1 (en) 2019-03-21 2022-05-12 Onxeo A dbait molecule in combination with kinase inhibitor for the treatment of cancer
WO2020225831A1 (en) * 2019-05-09 2020-11-12 Msn Laboratories Private Limited, R&D Center Improved process for the preparation of 4-{8-amino-3-[(2s)-1-(but-2-ynoyl)pyrrolidin-2-yl] imidazo[1,5-a]pyrazin-1-yl)}-n-(pyridine-2-yl)benzamide
CN113993871B (zh) * 2019-07-12 2023-08-01 正大天晴药业集团股份有限公司 含有5-氮杂螺庚烷的btk抑制剂
EP4054579A1 (en) 2019-11-08 2022-09-14 Institut National de la Santé et de la Recherche Médicale (INSERM) Methods for the treatment of cancers that have acquired resistance to kinase inhibitors
WO2021148581A1 (en) 2020-01-22 2021-07-29 Onxeo Novel dbait molecule and its use
KR20230027201A (ko) * 2020-06-19 2023-02-27 아세르타 파마. 비.브이. 아칼라브루티닙 말레산염 투약 형태
US20240100172A1 (en) 2020-12-21 2024-03-28 Hangzhou Jijing Pharmaceutical Technology Limited Methods and compounds for targeted autophagy

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0565233A (ja) 1991-03-08 1993-03-19 Mitsui Toatsu Chem Inc モノクローナル抗体含有凍結乾燥製剤
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
CA2454587C (en) 2001-07-25 2012-11-13 Protein Design Labs, Inc. Stable lyophilized pharmaceutical formulation of igg antibodies
BRPI0713421A2 (pt) 2006-06-14 2012-03-13 Imclone Systems Incorporated Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero
US7894450B2 (en) 2007-12-31 2011-02-22 Nortel Network, Ltd. Implementation of VPNs over a link state protocol controlled ethernet network
EP3613743B1 (en) 2008-01-04 2022-03-16 Intellikine, LLC Processes for the preparation of 1h-pyrazolo[3,4-d]pyrimidin-4-amine derivatives
US8193182B2 (en) 2008-01-04 2012-06-05 Intellikine, Inc. Substituted isoquinolin-1(2H)-ones, and methods of use thereof
BR112014001255B1 (pt) 2011-07-19 2019-07-02 Merck Sharp & Dohme B.V. Composto, uso de um composto, combinação, composição farmacêutica, e, sal farmaceuticamente aceitável de um composto
EP2548877A1 (en) * 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
WO2015057992A1 (en) * 2013-10-16 2015-04-23 Izumi Raquel Btk inhibitors for hematopoietic mobilization
WO2015110923A2 (en) 2014-01-21 2015-07-30 Acerta Pharma B.V. Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia usng a btk inhibitor
WO2016024227A1 (en) * 2014-08-11 2016-02-18 Acerta Pharma B.V. Btk inhibitors to treat solid tumors through modulation of the tumor microenvironment
CN108602827B (zh) * 2015-11-06 2021-08-20 安塞塔制药公司 Bruton酪氨酸激酶的咪唑并吡嗪抑制剂

Also Published As

Publication number Publication date
EP3865485A1 (en) 2021-08-18
EP3371189A1 (en) 2018-09-12
US20200330461A1 (en) 2020-10-22
MA43162A (fr) 2018-09-12
US11110088B2 (en) 2021-09-07
US20180318297A1 (en) 2018-11-08
CN108602827A (zh) 2018-09-28
US10736893B2 (en) 2020-08-11
WO2017077507A1 (en) 2017-05-11
JP6890602B2 (ja) 2021-06-18
JP2018536705A (ja) 2018-12-13

Similar Documents

Publication Publication Date Title
CN108602827B (zh) Bruton酪氨酸激酶的咪唑并吡嗪抑制剂
US20260049087A1 (en) Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same
JP6617130B2 (ja) Ｂｔｋ阻害剤としての４−イミダゾピリダジン−１−イル−ベンズアミドおよび４−イミダゾトリアジン−１−イル−ベンズアミド
AU2014324595B2 (en) Substituted nicotinimide inhibitors of BTK and their preparation and use in the treatment of cancer, inflammation and autoimmune disease
JP6029668B2 (ja) 複素環式化合物及びその使用
JP6027610B2 (ja) 複素環式化合物及びその使用
JP6027611B2 (ja) 複素環式化合物及びその使用
AU2012311504B2 (en) Pyrazolo[4,3-C]pyridine derivatives as kinase inhibitors
CA3046578A1 (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
CA2841887A1 (en) 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk - inhibitors
JP2020527174A (ja) Ａｔｒキナーゼの複素環式阻害剤
TW201629036A (zh) 喹啉及喹唑啉化合物類
KR20140135954A (ko) 치환된 피리미딘 화합물 및 syk 억제제로서의 이의 용도
WO2023183652A1 (en) Dual cxcr4-btk inhibitors
CA3202944A1 (en) Pyrazolothiazole carboxamides and their uses as pdgfr inhibitors
KR20240165430A (ko) Tea 도메인 패밀리 구성원들의 저분자 억제제들
WO2019239374A1 (en) Imidazopyrazine inhibitors of interleukin-2-inducible t-cell kinase
HK40049222A (en) Imidazopyrazine inhibitors of bruton's tyrosine kinase
CA3114259C (en) Aminonorbornane derivative and manufacture method therefor and use thereof
CN116249696A (zh) 嘧啶酮类化合物及其用途
CA3114259A1 (en) Aminonorbornane derivative and manufacture method therefor and use thereof
HK40091563B (zh) 嘧啶酮类化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant